Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials.

Lee, Y H; Song, G G

Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials.

Lee, Y H; Song, G G.

Affiliation

Lee YH; Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Goryeodae-ro, Seongbuk-gu, 02841, Seoul, Korea (Republic of). lyhcgh@korea.ac.kr.
Song GG; Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Goryeodae-ro, Seongbuk-gu, 02841, Seoul, Korea (Republic of).

Z Rheumatol ; 80(10): 988-994, 2021 Dec.

Article in En | MEDLINE | ID: mdl-33216191

Subject(s)

Antibodies, Monoclonal, Humanized; Lupus Erythematosus, Systemic; Humans; Lupus Erythematosus, Systemic/drug therapy; Randomized Controlled Trials as Topic; Treatment Outcome

Key words

Anifrolumab; Disease activity; Meta-analysis; Systemic lupus erythematosus; Treatment response

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Lupus Erythematosus, Systemic Type of study: Clinical_trials / Guideline / Systematic_reviews Limits: Humans Language: En Journal: Z Rheumatol Year: 2021 Document type: Article

Fulltext

XML

PubMed Links

Search on Google